Brief: Algernon Announces Plans For A Phase 2 Ifenprodil Chronic Cough Study In The U.S.
20/09/2021 12:49
Sept 20 (Reuters) - Algernon Pharmaceuticals Inc AGN.CD :
* ALGERNON PHARMACEUTICALS ANNOUNCES PLANS FOR A PHASE 2
IFENPRODIL CHRONIC COUGH STUDY IN THE U.S.
Source text for Eikon: ID:nGNX2QBt3h
Further company coverage: AGN.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Grey Matters Health
See all newsBrief: Grey Matters Announces The Closing Of Its Equity And Convertible Debenture Private Placement Totalling CAD $1.12 Million
Brief: Algernon Announces Additional Increase To Private Placement Financing
Brief: Algernon Health Announces Private Placement
Brief: Algernon Announces Closing Of The Private Placement Financing
Brief: Algernon Announces $1 Mln Private Placement